Why the study?
Does blockade of TGF-β1 with P144 reduce cardiac NADPH oxidase overactivity and profibrotic markers in spontaneously hypertensive rats?
Does blockade of TGF-β1 with P144 reduce cardiac NADPH oxidase overactivity and profibrotic markers in spontaneously hypertensive rats?
Blockade of TGF-β1 with P144 inhibits cardiac NADPH oxidase overactivity and profibrotic markers in a rat model of hypertension, highlighting a potential mechanism for its profibrotic actions.
Answers are grounded in this paper and cite their sources.
Supports TGF-β1 blockade for cardiac oxidative stress and fibrosis in hypertension; hypothesis-generating and should not yet change practice.
NADPH oxidases constitute a major source of superoxide anion (·O(2)(-)) in hypertension. Several studies suggest an important role of NADPH oxidases in different effects mediated by TGF-β 1. In this study we show that chronic administration of P144, a peptide synthesized from type III TGF-β 1 receptor, significantly reduced the cardiac NADPH oxidase expression and activity as well as in the nitrotyrosine levels observed in control spontaneously hypertensive rats (V-SHR) to levels similar to control normotensive Wistar Kyoto rats. In addition, P144 was also able to reduce the significant increases in the expression of collagen type I protein and mRNA observed in hearts from V-SHR. In addition, positive correlations between collagen expression, NADPH oxidase activity, and nitrotyrosine levels were found in all animals. Finally, TGF-β 1-stimulated Rat-2 exhibited significant increases in NADPH oxidase activity that was inhibited in the presence of P144. It could be concluded that the blockade of TGF-β 1 with P144 inhibited cardiac NADPH oxidase in SHR, thus adding new data to elucidate the involvement of this enzyme in the profibrotic actions of TGF-β 1.
No takes yet. Share an insight, caveat, or question.
Miguel‐Carrasco et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: